At a glance
- Originator Daiichi Pharmaceutical
- Class
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peptic ulcer
Most Recent Events
- 13 Jan 2004 No development reported - Preclinical for Peptic ulcer in Japan (unspecified route)
- 22 Oct 1998 Preclinical development for Peptic ulcer in Japan (Unknown route)